Beyond Air
Garden City
About Beyond Air
Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections. The company also focused on the development and commercialization of nitric oxide (NO) formulations for the treatment of lung infections. The revolutionary respiratory-targeted generator and delivery system, LungFit is designed to generate and effectively deliver nitric oxide to intubated and non-intubated patients in both the hospital and the home setting. The LungFit system uses proprietary technology to generate nitric oxide from ambient air and transform the lives of patients with respiratory conditions and severe lung infections. It can deliver nitric oxide either continuously or intermittently with the ability to titrate on demand. The system also satisfies a strong desire to eliminate cylinders from the hospital, providing significant benefits as a result. Beyond was founded in 2011 and is headquartered in Garden City, NY, USA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $157.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: otcqb:AITB
- Website: beyondair.net
- Phone: 516-665-8200
Industries & Categories
Biopharma, Biotechnology, Developer Platform, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/beyond-air-42033 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.